Findings

What do systematic reviews say?

318 questions · 353 findings · 50 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 31 · 8.8%GRADE not reported 53 · 15%Very low 99 · 28%Low 95 · 26.9%Moderate 68 · 19.3%High 7 · 2%

Selective serotonin reuptake inhibitors vs cognitive behavioural therapy

> 50% reduction in depressive symptoms · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Selective serotonin reuptake inhibitors vs cognitive behavioural therapy

Depressive symptoms · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
15 participants
Very low

Selective serotonin reuptake inhibitors vs cognitive behavioural therapy

Seizure frequency · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
15 participants
Very low

Selective serotonin reuptake inhibitors vs cognitive behavioural therapy

Treatment withdrawal · people with epilepsy and depression

It is very uncertain whether selective serotonin reuptake inhibitors changes withdrawals compared with cognitive behavioural therapy (very low certainty).

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
RR 0.44 [0.05, 3.85]
15 participants
Very low

Selective serotonin reuptake inhibitors vs cognitive behavioural therapy

Cognitive function · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Selective serotonin reuptake inhibitors vs cognitive behavioural therapy

Post‐treatment quality of life (QOLIE‐31 score, which has a range of 0‐200, with higher score indicates better quality of life) ( · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
15 participants
Very low

Selective serotonin reuptake inhibitors vs cognitive behavioural therapy

Adverse effects ‐ adverse event profile · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Selective serotonin reuptake inhibitors vs placebo

Outcomes (2‐6 months post‐treatment) · adults with panic disorder

The review found no eligible studies for this question.

1 finding from 1 review

Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Selective serotonin reuptake inhibitors vs placebo

Failure to respond at endpoint (6‐12 weeks) · adults with panic disorder

Selective serotonin reuptake inhibitors may leads to lower failure to respond compared with placebo (low certainty).

1 finding from 1 review

Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
RR 0.75 [0.67, 0.84]
21 studies · 4000 participants
Low

Selective serotonin reuptake inhibitors vs placebo

Leaving the study early · adults with panic disorder

Selective serotonin reuptake inhibitors showed no clear difference in total number of dropouts compared with placebo (moderate certainty).

1 finding from 1 review

Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
RR 0.99 [0.9, 1.09]
23 studies · 4302 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Failure to remit at endpoint · adults with panic disorder

Selective serotonin reuptake inhibitors probably leads to lower failure to remit compared with placebo (moderate certainty).

1 finding from 1 review

Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
RR 0.81 [0.75, 0.88]
16 studies · 3339 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

panic symptoms · adults with panic disorder

2 findings from 1 review

Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1625 participants
Moderate
Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1255 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Withdrawals due to adverse events · adults with panic disorder

Selective serotonin reuptake inhibitors probably leads to higher number of dropouts due to adverse effects compared with placebo (moderate certainty).

1 finding from 1 review

Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
RR 1.45 [1.16, 1.81]
22 studies · 4131 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Subjective sleep quality or quantity · adults with insomnia

1 finding from 1 review

Antidepressants for insomnia in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 135 participants
Low

Selective serotonin reuptake inhibitors vs placebo

Other subjective measures of sleep (total sleep time, sleep onset latency, nocturnal awakenings and subjective sleep efficiency) (PSQI) (at 12 weeks) · adults with insomnia

1 finding from 1 review

Antidepressants for insomnia in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Very low

Selective serotonin reuptake inhibitors vs placebo

Adverse events (at 12 weeks) · adults with insomnia

1 finding from 1 review

Antidepressants for insomnia in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Very low

Selective serotonin reuptake inhibitors vs placebo

PSG sleep outcomes (at 12 weeks) · adults with insomnia

1 finding from 1 review

Antidepressants for insomnia in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Autologous non‐myeloablative selective HSCT vs cyclophosphamide

Overall mortality · people with systemic sclerosis

Autologous non‐myeloablative selective HSCT showed no clear difference in overall mortality compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
RR 0.9 [0.44, 1.85]
1 study · 156 participants
Moderate

Autologous non‐myeloablative selective HSCT vs cyclophosphamide

Event‐free survival · people with systemic sclerosis

Autologous non‐myeloablative selective HSCT probably leads to lower event‐free survival compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
HR 0.34 [0.16, 0.74]
1 study · 156 participants
Moderate

Autologous non‐myeloablative selective HSCT vs cyclophosphamide

Functional ability · people with systemic sclerosis

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 131 participants
Low